Sector News

Sanofi taps Bayer vet to lead soon-to-be-bolstered consumer unit

October 3, 2016
Life sciences

GlaxoSmithKline, which filled the seat of CEO-bound Emma Walmsley on Thursday, isn’t the only Big Pharma to tap a new consumer chief this week.

On Friday, rival Sanofi announced it had appointed Alan Main to lead its OTC efforts, which will take the form of a newly created consumer health global business unit.

It’s a poach job by new Sanofi CEO Olivier Brandicourt, who recruited Main from his former employer, Bayer. At the German drugmaker, Main served as global president of medical care, but he has plenty of consumer experience from his pre-Bayer days at Roche Consumer Health, a business Bayer picked up in 2004.

Now, he’ll be tasked with leading a newly bulked-up business in an increasingly competitive space. Sanofi is currently working to close an asset swap for Boehringer Ingelheim’s consumer portfolio–for which it traded away its animal health offerings–and it expects to do so by the end of this year. Once it does, it’ll become a leader in the OTC field, it figures–meeting one of the key goals it laid out in its “roadmap 2020.”

Of course, Sanofi isn’t the only player fighting to gain ground in the consumer health arena. GlaxoSmithKline, which took the lead after starting up a JV with Novartis early last year, intends to keep the top spot, and it Thursday announced that Novartis vet Brian McNamara would be leading that charge as head of the venture.

Bayer, too, has said it’s gunning for the worldwide No. 1 position in the OTC market, though lately it’s focused its energies elsewhere. Earlier this month, it agreed to shell out $66 billion on agricultural giant Monsanto, a deal some industry watchers worry will hurt its pharma ambitions.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.